Journal September 16, 2026 8 min read

Semaglutide vs Cagrilintide: what the research actually compares

A comparison of semaglutide and cagrilintide on what each is, what published work measured, where evidence is stronger, and what remains unknown.

peptides-pro Editorial

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist. It is also known by its sequence as a GLP-1 analogue and is supplied as the free base or a salt form in research settings. Cagrilintide is a long-acting amylin receptor agonist, a peptide analogue of human amylin. Both are studied as once-weekly subcutaneous agents in metabolic and obesity research. The work centres on two distinct receptor families: the GLP-1 receptor for semaglutide and the amylin receptor for cagrilintide.

Semaglutide is often referenced by its molecular formula and weight in analytical reviews, while cagrilintide is primarily described by its receptor target and combination with semaglutide in fixed-dose products such as CagriSema. The evidence base for each compound differs in scope and maturity, and this page compares what the published literature reports for each.

Research Studies

Semaglutide and postpartum cardiometabolic risk after gestational diabetes

A randomized clinical trial is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). The study is an effectiveness-implementation Hybrid Type 1 design with 226 postpartum individuals randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome is development of metabolic syndrome at 6 months postpartum. Participants then enter a 6-month maintenance phase where semaglutide continuation, discontinuation, or initiation reflects patient and clinician decisions [1]. This trial measures metabolic syndrome incidence as a composite cardiometabolic endpoint in a postpartum population.

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

A multicentre, double-blind, placebo-controlled randomized trial is testing adjunctive oral semaglutide 3 mg once daily added to treatment as usual in patients with schizophrenia on second-generation antipsychotics. The primary comparison is against placebo over 24 weeks, with outcomes including 10-year cardiovascular risk (QRISK3), insulin resistance, lipids, weight, and metabolic biomarkers. Psychiatric safety and tolerability are also assessed [2]. This study focuses on a population with high metabolic syndrome burden and few effective options, and it uses an oral formulation at a lower dose than the injectable forms commonly studied for weight management.

Semaglutide and muscle preservation in older adults starting therapy

A randomized, double-blind, placebo-controlled trial is investigating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive the supplement combination or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3]. This work addresses a specific concern about lean mass loss during semaglutide treatment in an older population.

Semaglutide and switching to other incretin-based therapies

A study is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adults with obesity [4]. This trial is designed to assess a transition between compounds rather than semaglutide alone, and it measures safety and tolerability outcomes during the switch.

Semaglutide and alcohol use disorder with obesity

A study is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity. The objectives are to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5]. This research extends semaglutide investigation beyond metabolic endpoints into behavioural and stress-related measures in a dual-diagnosis population.

Semaglutide and comparison with zenagamtide for excess body weight

A study is investigating how well zenagamtide helps people with excess body weight lose weight compared to semaglutide [6]. The purpose is to determine the safety and effectiveness of zenagamtide relative to semaglutide in participants with excess body weight. This is a head-to-head comparison where semaglutide serves as the active comparator.

Semaglutide and early reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomized, parallel-controlled trial is comparing early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery) in 150 youth with severe obesity who had been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants are randomized to semaglutide 2.4 mg weekly or standard care for 24 months. Outcomes are assessed at multiple time points from 1 month to 24 months postoperatively [7]. This trial focuses on a paediatric surgical population and tests whether early reinitiation is safe and effective compared to no pharmacotherapy after surgery.

Semaglutide and cardiovascular health in breast cancer survivors on aromatase inhibitors

A phase IV trial is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors taking an aromatase inhibitor. In this population, obesity raises the risk of heart and blood vessel problems. The structured lifestyle support includes counselling on nutrition and physical activity with specific recommendations [8]. This trial measures cardiovascular outcomes in a cancer survivorship context where aromatase inhibitor use and obesity intersect.

Cagrilintide and amylin receptor agonism in obesity therapy

A systematic review and meta-analysis evaluated amylin-based obesity therapy, specifically cagrilintide and its fixed-dose combination with semaglutide (CagriSema), versus placebo. Cagrilintide is described as a once-weekly amylin receptor agonist, and the combination represents a novel therapeutic approach. The meta-analysis assessed efficacy outcomes in obesity [10]. This work provides pooled estimates for cagrilintide and CagriSema against placebo, but it does not directly compare cagrilintide monotherapy to semaglutide monotherapy in a head-to-head design.

Semaglutide analytical methods and detection

A comprehensive review reports that semaglutide is a potent long-acting glucagon-like peptide-1 receptor agonist with therapeutic efficacy for type 2 diabetes and obesity. Because of its widespread clinical use, there is increasing demand for analytical techniques to identify semaglutide in pharmaceutical formulations and biological matrices [9]. This reference-only source supports the characterisation of semaglutide as a GLP-1 receptor agonist and describes the analytical landscape, but it does not report comparative clinical outcomes.

Semaglutide treatment patterns and experienced effects in community pharmacy users

A cross-sectional survey investigated semaglutide treatment patterns among Danish adult users for weight management across 28 community pharmacies between March and May 2025. The study aimed to determine whether users follow the recommended treatment regimen [11]. This reference-only source provides observational data on real-world use patterns but does not compare semaglutide to cagrilintide.

Semaglutide and neuropsychiatric outcomes among incretin-based therapies

A study examined neuropsychiatric safety concerns, including depression and suicidal ideation, during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity. The research question was whether risks differ across successive generations of incretin-based therapies [12]. This reference-only source addresses a safety domain for semaglutide and related compounds but does not provide a direct comparison with cagrilintide.

Comparison of evidence characteristics

Feature	Semaglutide	Cagrilintide
Receptor target	GLP-1 receptor [9]	Amylin receptor [10]
Administration	Once-weekly subcutaneous; oral formulation also studied [2]	Once-weekly subcutaneous [10]
Published comparative data	Multiple randomized trials across diverse populations [1–8]	Meta-analysis versus placebo; combination with semaglutide [10]
Head-to-head versus the other compound	Not identified in the evidence block	Not identified in the evidence block
Populations studied	Postpartum GDM, schizophrenia, older adults, obesity, AUD, youth post-surgery, breast cancer survivors [1–8]	Obesity (meta-analysis) [10]
Key outcomes measured	Metabolic syndrome, cardiovascular risk, insulin resistance, weight, muscle mass, alcohol craving, safety [1–8]	Efficacy in obesity versus placebo [10]

Where the evidence is stronger for one

The evidence block contains far more clinical trial records for semaglutide than for cagrilintide. Semaglutide is studied across a wide range of populations and endpoints, including postpartum cardiometabolic risk [1], schizophrenia with metabolic syndrome [2], muscle preservation in older adults [3], switching between incretin therapies [4], alcohol use disorder [5], head-to-head comparison with zenagamtide [6], youth after sleeve gastrectomy [7], and breast cancer survivors on aromatase inhibitors [8]. These are randomized controlled trials with specified primary and secondary outcomes.

For cagrilintide, the evidence block provides a single reference-only meta-analysis of amylin-based obesity therapy that includes cagrilintide and CagriSema versus placebo [10]. This meta-analysis pools data but does not provide the same breadth of population-specific or endpoint-specific trial records as seen for semaglutide. The evidence for cagrilintide in the provided block is therefore narrower in scope and does not include head-to-head comparisons with semaglutide monotherapy.

What is simply not known

No head-to-head randomized controlled trial comparing semaglutide monotherapy to cagrilintide monotherapy is present in the evidence block. The meta-analysis of cagrilintide includes a fixed-dose combination with semaglutide (CagriSema) versus placebo [10], but this does not isolate the effect of cagrilintide alone relative to semaglutide alone. Long-term comparative safety and efficacy data between the two compounds are not available in the provided sources. The evidence block also does not contain information on cagrilintide in the specific populations studied for semaglutide, such as postpartum individuals, youth, or cancer survivors. Additionally, the reference-only sources for semaglutide address analytical methods [9], treatment patterns [11], and neuropsychiatric outcomes [12], but none of these compare semaglutide to cagrilintide.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.